HIV Infections Clinical Trial
Official title:
Impact Evaluation of a School-Based Sexuality and HIV Prevention Education Activity in South Africa
The purpose of this study is to evaluate the impact of the new South African Department of Basic Education (DBE) sexuality and HIV education program that uses scripted lesson plans and supporting activities and will be implemented by Education Development Center (EDC). The primary outcomes are the incidence of HSV-2 or pregnancy among a cohort of learners in grade 8 and followed for two years in two provinces of South Africa.
This evaluation focuses on the HIV and sexual and reproductive health (SRH) content of the
Government of South Africa life orientation (LO) Curriculum. In 2010, the Department of Basic
Education (DBE) undertook assessments of their LO program and learned that while young people
who participated in the program had improved knowledge and attitudes, the program was not
being implemented uniformly, such that the results were inconsistent across schools and
learners. To address these concerns, DBE, with support from the United States Agency for
International Development (USAID) and the United States President's Emergency Plan for AIDS
Relief (PEPFAR), developed scripted lesson plans (SLP) to strengthen the SRH content and
standardize implementation across schools; these SLP were paired with supporting activities
to address fidelity in the curriculum's delivery. The SLP were integrated in the LO program,
with most of the lessons offered in the first half of the school year. The lessons were
developed for grades 4-6, 7-9, and 10-12. This evaluation focuses on the curricula for grades
7-9 and 10-12. There are eight lessons for grade 7, eight for grade 8, 11 for grade 9, and 10
for grade 10. Notably, there were delays in getting DBE approvals for release of the grade-10
curriculum.
A key component of the program is that all LO teachers are trained on the new materials prior
to implementation. Since 2015, USAID/PEPFAR has provided technical support to DBE for program
roll out in priority provinces and districts that have the highest HIV incidence and
prevalence. Technical support includes educator training on the new SLP and considerations of
approaches for scale-up beyond the initial districts. Support for the first phase of
implementation and testing was led by Education Development Center, with funding from USAID.
The goal of the proposed impact evaluation is to assess the impact of the LO program on
students over time. The primary evaluation question is: What is the effect of the scripted
lesson plans and supporting activities on the incidence of HSV-2 or pregnancy after two years
among a cohort of girls enrolled in grade 8 at intervention schools compared to a cohort of
girls in grade 8 at control schools providing the current life skills program (i.e., the
standard of practice)?
The secondary evaluation questions include:
- What is the effect of the scripted lesson plans and supporting activities on knowledge,
attitudes, school retention, and self-reported risk behavior, HIV testing, and completed
referrals for health services at the end of 8th, 9th, and 10th grade among a cohort of
girls first interviewed in grade 8 and among a cross-section girls and boys interviewed
in grade 8, grade 9 and grade 10?
- If there is a reduction in the primary outcome, does the intervention work by increasing
school retention, or is the effect independent of school retention?
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |